Cite this publication
Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity
Lyndon, G. J.; Prieto, R.; Wajsbrot, D. B.; Allgulander, C. & Bandelow, B. (2019)
International Clinical Psychopharmacology, 34(3) pp. 110-118.
Documents & Media
- Lyndon, Gavin J.; Prieto, Rita; Wajsbrot, Dalia B.; Allgulander, Christer; Bandelow, Borwin
- Effects of baseline anxiety on the efficacy of venlafaxine extended release versus placebo were examined in a post hoc pooled subgroup analysis of 1573 patients enrolled in eight short-term studies of major depressive disorder. Anxiety subgroups were defined based on baseline 17-item Hamilton Rating Scale for Depression Item 10 score <3 (low) versus ≥3 (high). Change from baseline to final visit in Montgomery-Åsberg Depression Rating Scale total score and Montgomery-Åsberg Depression Rating Scale response and remission rates were analyzed. Change from baseline in Montgomery-Åsberg Depression Rating Scale total score and response and remission rates was significantly greater for venlafaxine extended release versus placebo in both low and high anxiety subgroups (all P < 0.0001). A statistically significant baseline anxiety by treatment interaction was observed for Montgomery-Åsberg Depression Rating Scale total score only (P = 0.0152). The adjusted mean change from baseline in Montgomery-Åsberg Depression Rating Scale total score was significantly greater in the high anxiety subgroup versus low anxiety subgroup for patients treated with venlafaxine extended release (-6.27 versus -3.89; P = 0.0440) but not placebo. These results support the efficacy of venlafaxine extended release for major depressive disorder treatment in patients with anxiety symptoms.
- CC BY-NC-ND 4.0
- Issue Date
- Document Version
- Published Version
- International Clinical Psychopharmacology
- 1473-5857; 0268-1315